FR3001895B1 - Solution injectable a ph7 comprenant au moins une insuline basale dont le point isoelectrique est compris en 5,8 et 8,5 et un compose anionique porteur de charges carboxylates et de radicaux hydrophobes - Google Patents

Solution injectable a ph7 comprenant au moins une insuline basale dont le point isoelectrique est compris en 5,8 et 8,5 et un compose anionique porteur de charges carboxylates et de radicaux hydrophobes

Info

Publication number
FR3001895B1
FR3001895B1 FR1351199A FR1351199A FR3001895B1 FR 3001895 B1 FR3001895 B1 FR 3001895B1 FR 1351199 A FR1351199 A FR 1351199A FR 1351199 A FR1351199 A FR 1351199A FR 3001895 B1 FR3001895 B1 FR 3001895B1
Authority
FR
France
Prior art keywords
isoelectric point
anionic compound
compound carrying
hydrophobic radicals
injectable solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR1351199A
Other languages
English (en)
Other versions
FR3001895A1 (fr
Inventor
Olivier Soula
Richard Charvet
Alexandre Geissler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Adocia SAS
Original Assignee
Adocia SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR1351199A priority Critical patent/FR3001895B1/fr
Application filed by Adocia SAS filed Critical Adocia SAS
Priority to US14/079,437 priority patent/US20140187499A1/en
Priority to CN201380059136.3A priority patent/CN104903341B/zh
Priority to EA201590937A priority patent/EA201590937A1/ru
Priority to BR112015010797-4A priority patent/BR112015010797A2/pt
Priority to JP2015542337A priority patent/JP2016505523A/ja
Priority to EP13801655.5A priority patent/EP2920200A1/fr
Priority to CA2889345A priority patent/CA2889345A1/fr
Priority to KR1020207029334A priority patent/KR20200121381A/ko
Priority to SG11201503598QA priority patent/SG11201503598QA/en
Priority to CN202010210296.5A priority patent/CN111494638A/zh
Priority to MX2015005423A priority patent/MX2015005423A/es
Priority to PCT/FR2013/052733 priority patent/WO2014076422A1/fr
Priority to KR1020157015765A priority patent/KR20150084056A/ko
Priority to AU2013346623A priority patent/AU2013346623A1/en
Priority to SG10201703742SA priority patent/SG10201703742SA/en
Priority to SG10202112306UA priority patent/SG10202112306UA/en
Priority to EP14703898.8A priority patent/EP2956128A1/fr
Priority to US14/179,212 priority patent/US20140235536A1/en
Priority to PCT/EP2014/052763 priority patent/WO2014124994A1/fr
Publication of FR3001895A1 publication Critical patent/FR3001895A1/fr
Priority to IL238303A priority patent/IL238303B/en
Priority to SA515360426A priority patent/SA515360426B1/ar
Application granted granted Critical
Publication of FR3001895B1 publication Critical patent/FR3001895B1/fr
Priority to HK16101679.8A priority patent/HK1213907A1/zh
Priority to US15/950,527 priority patent/US20180236085A1/en
Priority to AU2018204764A priority patent/AU2018204764A1/en
Priority to IL261726A priority patent/IL261726A/en
Priority to AU2020203078A priority patent/AU2020203078A1/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/70—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with two hydrocarbon radicals attached in position 2 and elements other than carbon and hydrogen in position 6
    • C07D311/72—3,4-Dihydro derivatives having in position 2 at least one methyl radical and in position 6 one oxygen atom, e.g. tocopherols
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/18—Acyclic radicals, substituted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne une composition sous forme d'une solution aqueuse injectable, dont le pH est compris entre 6,6 et 7,8, comprenant au moins : a) une insuline basale dont le point isoélectrique pI est compris entre 5,8 et 8,5 ; b) un composé anionique porteur de charges carboxylates et de radicaux hydrophobes. Dans un mode de réalisation, les compositions selon l'invention comprennent en outre une insuline prandiale.
FR1351199A 2012-11-13 2013-02-12 Solution injectable a ph7 comprenant au moins une insuline basale dont le point isoelectrique est compris en 5,8 et 8,5 et un compose anionique porteur de charges carboxylates et de radicaux hydrophobes Expired - Fee Related FR3001895B1 (fr)

Priority Applications (27)

Application Number Priority Date Filing Date Title
FR1351199A FR3001895B1 (fr) 2013-02-12 2013-02-12 Solution injectable a ph7 comprenant au moins une insuline basale dont le point isoelectrique est compris en 5,8 et 8,5 et un compose anionique porteur de charges carboxylates et de radicaux hydrophobes
PCT/FR2013/052733 WO2014076422A1 (fr) 2012-11-13 2013-11-13 Composes anioniques substitues constitues d'un squelette forme d'un nombre discret d'unites saccharidiques
SG10201703742SA SG10201703742SA (en) 2012-11-13 2013-11-13 Substituted anionic compounds consisting of a backbone consisting of a discrete number of saccharide units
BR112015010797-4A BR112015010797A2 (pt) 2012-11-13 2013-11-13 compostos aniônicos substituídos, e, composição farmacêutica
JP2015542337A JP2016505523A (ja) 2012-11-13 2013-11-13 離散数の糖単位から構成される主骨格から成る置換されたアニオン性化合物
EP13801655.5A EP2920200A1 (fr) 2012-11-13 2013-11-13 Composes anioniques substitues constitues d'un squelette forme d'un nombre discret d'unites saccharidiques
CA2889345A CA2889345A1 (fr) 2012-11-13 2013-11-13 Composes anioniques substitues constitues d'un squelette forme d'un nombre discret d'unites saccharidiques
KR1020207029334A KR20200121381A (ko) 2012-11-13 2013-11-13 개별 갯수의 사카라이드 단위로 이루어지는 백본으로 이루어지는 치환된 음이온성 화합물
SG11201503598QA SG11201503598QA (en) 2012-11-13 2013-11-13 Substituted anionic compounds consisting of a backbone consisting of a discrete number of saccharide units
CN202010210296.5A CN111494638A (zh) 2012-11-13 2013-11-13 由离散数个糖单元组成的骨架组成的经取代阴离子化合物
MX2015005423A MX2015005423A (es) 2012-11-13 2013-11-13 Compuestos anionicos sustituidos que consisten de un esqueleto formado por un numero discreto de unidades sacaridicas.
CN201380059136.3A CN104903341B (zh) 2012-11-13 2013-11-13 由离散数个糖单元组成的骨架组成的经取代阴离子化合物
KR1020157015765A KR20150084056A (ko) 2012-11-13 2013-11-13 개별 갯수의 사카라이드 단위로 이루어지는 백본으로 이루어지는 치환된 음이온성 화합물
AU2013346623A AU2013346623A1 (en) 2012-11-13 2013-11-13 Substituted anionic compounds consisting of a backbone consisting of a discrete number of saccharide units
US14/079,437 US20140187499A1 (en) 2012-11-13 2013-11-13 Substituted anionic compounds consisting of a backbone made up of a discrete number of saccharide units
SG10202112306UA SG10202112306UA (en) 2012-11-13 2013-11-13 Substituted anionic compounds consisting of a backbone consisting of a discrete number of saccharide units
EA201590937A EA201590937A1 (ru) 2012-11-13 2013-11-13 Замещенные анионные соединения, имеющие скелет, образованный из небольшого числа сахаридных звеньев
EP14703898.8A EP2956128A1 (fr) 2013-02-12 2014-02-12 Solution injectable a ph7 comprenant au moins une insuline basale dont le point isoelectrique est compris entre 5,8 et 8,5 et un compose anionique porteur de charges carboxylates et de radicaux hydrophobes
US14/179,212 US20140235536A1 (en) 2013-02-12 2014-02-12 Injectable solution at ph 7 comprising at least one basal insulin the isoelectric point of which is comprised in 5.8 and 8.5 and an anionic compound bearing carboxylate charges and hydrophobic radicals
PCT/EP2014/052763 WO2014124994A1 (fr) 2013-02-12 2014-02-12 Solution injectable a ph7 comprenant au moins une insuline basale dont le point isoelectrique est compris entre 5,8 et 8,5 et un compose anionique porteur de charges carboxylates et de radicaux hydrophobes
IL238303A IL238303B (en) 2012-11-13 2015-04-15 Modified anionic compounds containing a skeleton composed of a distinct number of saccharide units
SA515360426A SA515360426B1 (ar) 2012-11-13 2015-05-12 مركبات أنيونية بها استبدال تكوِّن سلسلة رئيسية تتكون من عدد منفصل من وحدات سكاريد
HK16101679.8A HK1213907A1 (zh) 2012-11-13 2016-02-17 由離散數個糖單元組成的骨架組成的經取代陰離子化合物
US15/950,527 US20180236085A1 (en) 2013-02-12 2018-04-11 Injectable solution at ph 7 comprising at least one basal insulin the isoelectric point of which is comprised in 5.8 and 8.5 and an anionic compound bearing carboxylate charges and hydrophobic radicals
AU2018204764A AU2018204764A1 (en) 2012-11-13 2018-06-29 Substituted anionic compounds consisting of a backbone consisting of a discrete number of saccharide units
IL261726A IL261726A (en) 2012-11-13 2018-09-12 Modified anionic compounds containing a skeleton composed of a distinct number of saccharide units
AU2020203078A AU2020203078A1 (en) 2012-11-13 2020-05-10 Substituted anionic compounds consisting of a backbone consisting of a discrete number of saccharide units

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1351199A FR3001895B1 (fr) 2013-02-12 2013-02-12 Solution injectable a ph7 comprenant au moins une insuline basale dont le point isoelectrique est compris en 5,8 et 8,5 et un compose anionique porteur de charges carboxylates et de radicaux hydrophobes

Publications (2)

Publication Number Publication Date
FR3001895A1 FR3001895A1 (fr) 2014-08-15
FR3001895B1 true FR3001895B1 (fr) 2015-07-03

Family

ID=48521179

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1351199A Expired - Fee Related FR3001895B1 (fr) 2012-11-13 2013-02-12 Solution injectable a ph7 comprenant au moins une insuline basale dont le point isoelectrique est compris en 5,8 et 8,5 et un compose anionique porteur de charges carboxylates et de radicaux hydrophobes

Country Status (4)

Country Link
US (2) US20140235536A1 (fr)
EP (1) EP2956128A1 (fr)
FR (1) FR3001895B1 (fr)
WO (1) WO2014124994A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2814461B1 (fr) 2012-01-09 2019-07-24 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide substitue
US20150314003A2 (en) 2012-08-09 2015-11-05 Adocia Injectable solution at ph 7 comprising at least one basal insulin the isoelectric point of which is between 5.8 and 8.5 and a hydrophobized anionic polymer
FR3052072A1 (fr) 2016-06-07 2017-12-08 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
FR3070264A1 (fr) 2017-08-24 2019-03-01 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris de 5,8 a 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
FR3083089A1 (fr) 2018-06-29 2020-01-03 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
FR3083088B1 (fr) 2018-06-29 2020-10-02 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
EP3720472A1 (fr) 2017-12-06 2020-10-14 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
MA51127A (fr) 2017-12-07 2021-03-17 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
WO2019110773A1 (fr) 2017-12-07 2019-06-13 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
SG11202005322RA (en) 2017-12-07 2020-07-29 Adocia Injectable solution at ph 7 comprising at least one basal insulin having a pi of between 5.8 and 8.5 and a copolyamino acid carrying carboxylate charges and hydrophobic radicals
US20200179489A1 (en) 2018-12-07 2020-06-11 Adocia Injectable solution at ph 7 comprising at least one basal insulin which pi is from 5.8 to 8.5 and a co-polyamino-acid bearing carboxylate charges and hydrophobic radicals and a limited amount of m-cresol

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3482551D1 (de) 1983-10-26 1990-07-26 Kanebo Ltd Proteinhaltiges emulgiermittel, dessen herstellung und dieses enthaltende emulgierte kosmetische zusammensetzung.
DE3837825A1 (de) 1988-11-08 1990-05-10 Hoechst Ag Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
SK2432004A3 (sk) 2001-12-20 2005-04-01 Eli Lilly And Company Inzulínová zlúčenina s protrahovaným účinkom
FR2840614B1 (fr) * 2002-06-07 2004-08-27 Flamel Tech Sa Polyaminoacides fonctionnalises par de l'alpha-tocopherol et leurs applications notamment therapeutiques
CA2518776A1 (fr) 2003-04-29 2004-11-11 Eli Lilly And Company Analogues de l'insuline ayant une action prolongee
JP2009533471A (ja) 2006-04-12 2009-09-17 バイオデル， インコーポレイテッド 即効型および長時間作用型組合せインスリン製剤
SI2057165T1 (sl) 2006-09-07 2011-07-29 Ind Res Ltd Gracefield Res Ct Acikliäśni aminski zaviralci nukleozidnih fosforilaz in hidrolaz
US8575096B2 (en) 2007-08-13 2013-11-05 Novo Nordisk A/S Rapid acting insulin analogues
PL2597103T3 (pl) * 2007-11-16 2017-04-28 Novo Nordisk A/S Stabilne kompozycje farmaceutyczne zawierające liraglutyd i degludec
US8759322B2 (en) 2008-11-05 2014-06-24 National University Corporation Tokyo Medical And Dental University Hyaluronic acid derivative and pharmaceutical composition thereof
EP2388723A1 (fr) 2010-05-18 2011-11-23 University College Cork-National University of Ireland, Cork Procédé d'évaluation de l'état allergique d'une personne
AU2011202239C1 (en) 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
EP2389945A1 (fr) 2010-05-28 2011-11-30 Sanofi-Aventis Deutschland GmbH Composition pharmaceutique comprenant de l'AVE0010 et de l'insuline glargine
RU2578460C2 (ru) * 2011-08-10 2016-03-27 Адосиа Приемлемый для инъекций раствор по меньшей мере одного базального инсулина
FR2985429B1 (fr) * 2012-01-09 2016-07-29 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un polyaminoacide substitue obtenu par un procede de polymerisation controle
EP2814461B1 (fr) * 2012-01-09 2019-07-24 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide substitue
FR2985428B1 (fr) * 2012-01-09 2016-05-27 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un polyaminoacide substitue

Also Published As

Publication number Publication date
WO2014124994A1 (fr) 2014-08-21
EP2956128A1 (fr) 2015-12-23
US20140235536A1 (en) 2014-08-21
US20180236085A1 (en) 2018-08-23
FR3001895A1 (fr) 2014-08-15

Similar Documents

Publication Publication Date Title
FR3001895B1 (fr) Solution injectable a ph7 comprenant au moins une insuline basale dont le point isoelectrique est compris en 5,8 et 8,5 et un compose anionique porteur de charges carboxylates et de radicaux hydrophobes
FR3001896B1 (fr) Solution injectable a ph 7 comprenant au moins une insuline basale dont le point isolectrique est compris entre 5,8 et 8,5 et un polymere anionique hydrophobise
PH12018502558A1 (en) Injectable solution at ph 7, comprising at least one basal insulin whose pi is between 5.8 and 8.5, a prandial insulin and/or a gastrointestinal hormone, and a copolyamino acid bearing carboxylate charges and hydrophobic radicals
PH12020550827A1 (en) Injectable solution at ph 7 comprising at least one basal insulin having a pi of between 5.8 and 8.5 and a copolyamino acid carrying carboxylate charges and hydrophobic radicals
MX2018015070A (es) Composiciones en forma de solucion acuosa inyectable, que comprende glucagon humano y un co-poliaminoacido injertado en el extremo.
MA38539B1 (fr) Dispositif de conservation à élévations tridimensionnelles
MX2022010324A (es) Sitios especificos para modificar anticuerpos para hacer inmunoconjugados.
MA49678A (fr) Compositions sous forme d'une solution aqueuse injectable comprenant au moins l'insuline humaine a21g et un suppresseur de glucagon a action prandiale
MA51127A (fr) Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
WO2019110797A8 (fr) Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide
FR2985428B1 (fr) Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un polyaminoacide substitue
FR2962738B1 (fr) Composition adhesive comprenant du chitosane desacetyle
MA51597A (fr) Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
PH12020550804A1 (en) Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analog and a copolyamino acid
FR3033327B1 (fr) Composition solide de nanocharges carbonees pour les formulations utilisees dans les batteries au plomb.
IN2013MU03124A (fr)
WO2014197763A8 (fr) Conception moléculaire de sondes bimodales pour imagerie radio-isotopique (pet ou spect) et irm
NO20082928L (no) Fremgangsmate for sol-gel prosessering
EA201890855A1 (ru) Система и способ изготовления прикрепляемого ножа с точной подгонкой и соответствующего экскаваторного ковша
AR105896A1 (es) Fertilizador de urea y nitrato de amonio
FR3020377B1 (fr) Composition lubrifiante comprenant un compose anti-cliquetis
FR3074422B1 (fr) Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
FR3074681B1 (fr) Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
FR3074683B1 (fr) Compositions sous forme d'une solution aqueuse injectable comprenant du glucagon humain et un co-polyaminoacide
FR3061660B1 (fr) Compositions sous forme d'une solution aqueuse injectable comprenant du glucagon humain et un co-polyaminoacide

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 6

PLFP Fee payment

Year of fee payment: 8

ST Notification of lapse

Effective date: 20211005